Apart from his work in academia, Dr. Lewis is a co-founder of NovoBiotic Pharmaceuticals, Arietis Pharma, Holobiome, Flightpath Biosciences and Odyssey Therapeutics.
Persisters are cells with low level of ATP, which drops as a result of stochastic variation in expression of energy producing components.
Acyldepsipeptide (ADEP) kills persisters in S. aureus and other bacteria by activating the Clp protease, forcing the cell to self-digest.
These include siderophores for environmental bacteria [10] and quinones for symbionts of the human microbiome[11][12] Antimicrobial Drug Discovery: In collaboration with NovoBiotic, Dr. Lewis discovered teixobactin, a novel cell wall acting antibiotic that is produced by an uncultured bacterium Eleftheria terrae.
[15] Clovibactin is another example of an antibiotic to which resistance does not develop[16] Lewis and his group also discovered several compounds acting against Gram negative pathogens.